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In 1996, Purdue Pharma released the powerful slow-release opioid OxyContin, and for 
the nearly two decades that have followed, the United States has battled a prescription drug 
abuse problem of epidemic proportion (Center for Disease Control and Prevention, 2011). 
Central Appalachian states like Kentucky, with low income, rural populations economically 
dependent on manual labor, are particularly susceptible to the addictive potential of the drug and 
others like it. In response to the marked rise in opioid diversion, addiction, and overdose, 
Kentucky established its prescription drug monitoring program (PDMP) Kentucky All Schedule 
Prescription Electronic Reporting (KASPER) in 1999 as a tool for medical professionals to 
monitor, store, and reference data related to patients’ prescription history (Kentucky Cabinet for 
Health and Family Services, 2006). Presently, 49 states plus Washington D.C. have some form 
of prescription drug monitoring program in place in order to identify trends indicative of “doctor 
shopping” and prevent the over-prescription of scheduled narcotics (Prescription Drug 
Monitoring Program Center of Excellence, 2013). 
Kentucky’s model garnered significant praise and in 2013, KASPER was labeled “a gold 
standard” PDMP (Substance Abuse and Mental Health Services Administration, 2013). Still, 
Kentucky’s drug overdose mortality rate more than quadrupled between 1999 and 2013. 
Approximately three quarters of these overdose deaths involved prescription drugs (Trust for 
America’s Health, 2013). Evidence suggests that access to pills from states with less robust 
prescription drug monitoring legislation was to blame. The United States Drug Enforcement 
Administration reported that in 2010, of the top 100 oxycodone purchasing physicians 
nationwide, 90 were located in Florida (Rannazzisi, 2012). In his testimony on prescription drug 
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diversion in March of 2012, Kentucky Attorney General Jack Conway stated that law 
enforcement officials estimated 60 percent of pills sold illegally in Kentucky originated in 
Florida (Prescription Drug Diversion, 2012). Florida failed to enact a PDMP until 2011 and is 
one of just three states whose program does not share data with authorized users in any other 
state.   
This paper will use peer-reviewed literature, state law archives, raw data from a 2008-
2014 longitudinal study of more than 500 prescription opioid users in rural southeastern 
Kentucky, and drug use and overdose statistics from state and federal agencies such as the 
Kentucky Office of Inspector General, Drug Enforcement Administration, and Centers for 
Disease Control and Prevention to identify key stakeholders and motives, establish temporal 
relationships between illicit opioid use trends and changes to prescription drug monitoring 
policies, explore barriers to implementation of stricter regulations in Florida, and outline next 
steps toward achieving a more transparent and effective PDMP there. The purpose of this paper 
is to make the ethical public health case for Florida to strengthen its PDMP in order to 
significantly reduce the burden of diverted prescription opioids in Kentucky. 
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Opioids in Modern Medicine 
Opioid, or narcotic, analgesics are powerful morphine-like agents designed to block pain. 
These prescription painkillers can produce euphoria similar to opiates like heroin and have the 
potential to be both addictive and deadly. Prior to the late twentieth century, opioid analgesics 
were reserved for malignant cancer and end of life care. The prevailing stance among medical 
professionals was that their limited benefit to treat chronic non-cancer pain did not justify the 
risk of diminished effectiveness over time or potential for iatrogenic addiction. Non-cancer 
chronic pain was, instead, more frequently treated with less potent non-narcotic analgesics like 
nonsteroidal anti-inflammatory drugs (NSAIDs) (Kolodny et al., 2015).  The mid-1980s through 
late 1990s saw the start of a significant shift in the way medical professionals used opioids to 
manage pain, thanks in large part to three key turning points.  
 
Opiophobia 
In 1985, Dr. JP Morgan coined the term “opiophobia” to describe what he perceived as 
the medical establishment’s tendency to under-treat pain (Morgan, 1985). In 1986 the journal 
Pain published findings of a retrospective evaluation of long-term opioid-based pain 
management patients in which doctors concluded that “opioid maintenance therapy can be a safe, 
salutary and more humane alternative to the options of surgery or no treatment in those patients 
with intractable non-malignant pain and no history of drug abuse,” (Portenoy & Foley, 1986, p. 
1). Despite the study’s limited sample size (38 patients), its findings helped influence a 
fundamental shift in the way pain was assessed and treated.   
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Pain as the Fifth Vital Sign 
In 1995, the American Pain Society (APS) declared pain “the fifth vital sign.” In his APS 
presidential address the following year, James Campbell asserted “If pain were assessed with the 
same zeal as other vital signs are, it would have a much better chance of being treated 
properly…Quality care means that pain is measured and treated” (Department of Veterans 
Affairs, 2000). The “Pain as the Fifth Vital Sign” campaign implored doctors to screen and 
address pain at every encounter in the same way body temperature, respiration, blood pressure, 
and pulse are monitored.   
In 1999, the North Carolina Department of Human Resources fined a nursing home for 
patient endangerment after a nurse diagnosed a patient as addicted to his previous morphine 
regimen and intended to replace opioids with a tranquilizer. It was the first time a medical board 
had taken disciplinary action on the basis of undertreated pain. The patient’s estate was awarded 
a $15 million civil suit settlement for damages (Pasero & McCaffery, 2001). Precedents of 
accountability such as this signaled a substantial shift in healthcare professionals’ approach to 
pain management. This departure from so called “opiophobia” toward a more liberal application 
of prescriptive pain treatment allowed manufacturers of powerful new pain relievers to leverage 
buy-in from both patients, who were growing increasingly aware of the benefits of these pain 
relievers, and medical professionals, who feared legal retribution or censure for inadequately 
addressing pain.  
 
Purdue Pharma introduces OxyContin 
 Oxycodone is a narcotic analgesic used to treat moderate to severe pain sold as either a 
combination formula with acetaminophen under names like Tylox and Percocet or as a single 
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ingredient formula. Oxycodone alone is water soluble and easily injectable. Oxycodone is also 
considered more powerful than an equivalent dose of other popular opioids like hydrocodone, 
quickly making it the most preferred opioid among nonmedical opioid users (Cicero, Ellis, 
Surratt, Kurtz, 2013).  
Perhaps the most influential opioid to be released in recent history was Purdue Pharma’s 
oxycodone OxyContin. Since its introduction to the U.S. market in 1939, oxycodone had been 
available only as an instant release pill. The U.S. Food and Drug Administration (FDA) 
approved Purdue Pharma’s single ingredient extended release oxycodone as 10, 20, and 40mg 
tablets in December, 1995, with the popular 80mg tablet approved the following year. The FDA 
approved a 160mg tablet in 2000, however, due to its severe abuse potential, manufacture of the 
pill was discontinued in May, 2001 (as cited in University of Maryland Center for Substance 
Abuse Research, 2013). What followed OxyContin’s market introduction was an extraordinarily 
aggressive promotional campaign that included at least 40 all-expenses-paid pain management 
conferences in resort destinations for more than 5,000 physicians, pharmacists, and nurses; 
distribution of approximately 34,000 free 7- to 30-day supply patient starter coupons; and annual 
bonuses for sales representatives averaging $71,500 between 1996 and 2001 (Van Zee, 2009). 
Over the same period of time the OxyContin sales team more than doubled in size, the number of 
prescriptions written increased nearly 2,200%, and annual sales grew from $45 million to more 
than $1.3 billion (U.S. Food and Drug Administration, 2003).  
In May of 2000, Purdue Pharma received its first warning letter from the FDA for 
misleading efficacy and safety claims in their advertising in a leading professional medical 
journal (U.S. Food and Drug Administration, 2000). Purdue Pharma drew the ire of the FDA 
again in 2001 when it was revealed an OxyContin promotional video touting unsubstantiated 
IMPROVING E-FORCSE TO REDUCE OPIOID BURDEN IN KY 10 
 
claims had been distributed to medical professionals for three years without having first been 
submitted for review. In January of 2003 the company was issued a second warning letter from 
the FDA for “grossly overstat[ing]” the drug’s safety profile in advertisements running in 
multiple professional medical journals beginning the previous year (U.S. Food and Drug 
Administration, 2003). 
Meanwhile, in popular media, the name OxyContin had become synonymous with the 
prescription drug problem sweeping large sections of the nation. In 2008, the FDA concluded 
that OxyContin (both brand and generic) had higher rates of non-medical use than any other 
prescription opioid, citing increased drug availability along with Purdue Pharma’s inadequate 
product labeling as leading contributing factors (U.S. Food and Drug Administration, 2008). In 
2007, Purdue Pharma and its top executives pleaded guilty to misbranding OxyContin as a less 
addictive alternative to other prescription opioids and settled with federal prosecutors for $634 
million in fines, about a quarter of which was earmarked as reimbursement to federal and state 
governments for damages caused to Medicaid programs. Only Kentucky refused its share of the 
settlement, opting instead to present its own billion-dollar civil suit, currently under final pre-
trial appeal (Armstrong, 2014).  
 Sizeable fines such as this may serve as deterrents against future misdeeds, however, they 
exhaust significant public resources in dispute and are reactionary rather than proactive, 
requiring the proof of negligence to manifest before becoming a viable course of punitive action. 
Purdue Pharma’s gross abuse of industry standards and manipulation of existing federal 
regulations proves that not all pharmaceutical manufacturers cannot be entrusted to self-regulate 
in the best interest of public health, especially considering such lofty financial stakes. Such 
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ineptitude underscores the need for a more robust system of checks at subsequent junctions of 
the pharmaceutical supply chain. 
 
Prescription Drug Monitoring Programs  
Prescription drug monitoring programs (PDMPs) are state level tools designed to help 
eliminate overprescribing and “doctor shopping” at the frontline by equipping authorized 
medical professionals with a patient’s prescription history. Notable in their worth, PDMPs are  
primary prevention tools in that prescription drug distributors share a single, common, registered 
and regulated manufacturing source (pharmaceutical companies), and retail source (licensed 
prescribers and dispensers). PDMPs have the propensity to identify and eliminate drug diversion 
at multiple points of the supply chain – prescriber, small-time dealer (securing large quantities of 
pills for distribution), and user (drug-seeking behavior such as filling prescriptions early). Law 
enforcement agencies do not have access to PDMPs other than in bona fide court cases in which 
a subpoena has been issued and an application requesting access has been filed.  
Forty-nine states have enacted PDMP legislation. Though each PDMP differs slightly in 
its scope, the common goal is to equip prescribers with real-time data to identify individual 
patient drug-seeking behavior and pharmacists with data regarding whether prescriptions have 
been filled. Each state’s database is populated by prescribers and pharmacists. Regulations, such 
as substances monitored, who is authorized to access the database, and the time-frame within 
which prescriptions must be entered, vary by state. PDMPs also vary from state to state in their 
interstate operability, accessibility (who is authorized as well as who is required), registration 
and compliance requirements, infrastructure, oversight, funding source, and public backing.    
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Kentucky’s Prescription Drug Abuse Epidemic 
 Kentucky was one of the earliest states to recognize prescription opioid diversion, 
particularly OxyContin and other oxycodone, as a significant public health threat. Between 1998 
and 2000, admissions to Kentucky treatment facilities for oxycodone abuse rose 163% (National 
Drug Intelligence Center, 2002). Kentucky’s rural Appalachian eastern region, accounting for 54 
of the state’s 120 counties, felt the impact of overzealous prescribers and traffickers more 
severely than almost any other part of the country. Nearly half of all eastern Kentucky residents 
reported having at least one friend or family member who experienced problems related to 
prescription painkillers (Foundation for a Healthy Kentucky, 2013). In 2000, Kentucky’s 10 
greatest OxyContin distributing counties per capita by volume were all Appalachian counties 
with rates 3.1 to 5.9 times the national average. Hydrocodone distribution within these counties 
was exceptional too, ranging from 1.6 times the national average in Cumberland County (the 
number one ranked OxyContin distributing county) to 8.8 times the national average in Greenup 
County (Van Zee, 2009). Between 2000 and 2010, state drug overdose deaths rose from 6 to 22.9 
per 100,000 residents. Further, Powell County in eastern Kentucky lead the state with 75.4 
deaths per 100,000 residents (Estep, 2012). Roughly 88% of Kentucky’s overdose deaths were 
ruled unintentional (Bunn & Slavova, 2012). In 2013, 6 other Appalachian counties topped the 
list, with Bell County in the far southeastern corner of the state reporting 93.2 overdose deaths 
per 100,000 residents (Kentucky Office of Drug Control Policy, 2013).  
 A number of social and economic factors may contribute to eastern Kentucky’s 
prescription drug problem. Historically, coal mining has been a primary economic contributor in 
southeastern Kentucky. A physically demanding job that pays well, it is also among the most 
deadly professions in the country, with a rate of 35.4 fatalities per 100,000 miners in 2010 
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(United States Mine Safety and Health Administration, 2014). Prescription opioids are key to 
reducing the number of workdays missed due to acute and/or chronic pain. Physicians 
accustomed to managing legitimate pain associated with common work-related injuries difficult 
to definitively diagnose (e.g. back pain) may be more susceptible to exploitation by users and 
small time dealers looking to supplement illicit activity by faking injury. Even legitimately 
prescribed and appropriately used painkillers in large quantities throughout a given region can be 
problematic in that they open the door to iatrogenic addiction, unintentional over-medication and 
overdose, and the potential for increased diversion. At the macro level, free market fundamentals 
dictate that increased demand yields a more robust network of suppliers, thus increasing,  the 
likelihood of unscrupulous practitioners setting up shop and, practically speaking, the likelihood 
of unscrupulous patients successfully “doctor shopping” close to home.  
 Social networks and strong familial ties associated with the rurality of Kentucky’s 
southeastern region may also facilitate prescription opioid abuse. Friends and relatives with 
prescriptions are the most commonly cited sources for prescription drugs used illicitly (CDC, 
2013). Rural social networks tend to include more familial ties than their urban counterparts, 
resulting in some members possessing both familial and social capital within the network, thus 
potentially strengthening the influence of any single user within a peer group. Intergenerational 
shared drug use may also be more prevalent within rural areas, which, along with elevated 
prescription rates, helps normalize the behavior. Rural residents who may not have ever 
considered using heroin or other street drugs, may see opioids as safer, whether purchased 
illegally from dealers or diverted illegally from a friend or family member, since they are 
prescribed by medical professionals. 
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 Kentucky’s history of economic depression, particularly in its easternmost region, is long 
and well documented. In 2013, 18.8% of Kentucky residents were living below poverty level 
compared to 15.4% nationally (United States Census Bureau, 2015b). In the state’s 5
th
 
congressional district, made up entirely of Appalachian counties, that rate was 26.7% with some 
counties reporting more than a third of their residents living below the federal poverty level 
(United States Census Bureau, 2015a). People with low socioeconomic status are at increased 
risk for illicit drug use according to the CDC (2013). In 2000, a single 80mg OxyContin tablet 
retailed for $6 but carried a street value of $80 (National Drug Intelligence Center, 2001). The 
temptation of such enormous profitability in an economically depressed area may have driven 
many patients who would have never self-identified as drug dealers to sell leftover medication in 
order, simply, to make ends meet. The promise of greater access to healthcare nationally coupled 
with the state’s quick adoption and promotion of the Affordable Care Act may also mean greater 
access to divertible prescription drugs from legitimate sources in the future, underscoring the 
need for a thorough prescription drug monitoring system to prevent access to divertible drugs at 
the retail source level.    
 
KASPER 
 In 1997, early concern from law enforcement, medical practitioners, and elected officials 
regarding increased prescription drug misuse and investigators’ inability to efficiently access 
prescription histories of suspected drug abusers prompted Kentucky’s Attorney General to 
establish a Prescription Drug Abuse Task Force. The 45 member body, made up of 
representatives of the aforementioned sectors as well as prosecutors, judges, researchers, 
educators, and substance abuse treatment specialists, issued a report calling for, among other 
IMPROVING E-FORCSE TO REDUCE OPIOID BURDEN IN KY 15 
 
things, more succinct monitoring of prescriptions of schedule II-V controlled substances. As a 
result, in July 1998, Kentucky Legislature passed a statute mandating implementation of an 
electronic prescription drug monitoring system by January 1, 1999. Kentucky All Schedule 
Prescription Electronic Reporting, or KASPER as it would come to be known, became part of 
then Governor Paul E. Patton’s prescription drug tracking initiative, a key component of his 
overall crime reduction strategy. Early organizational supporters included the Justice Cabinet, 
state law enforcement agencies, the Board of Pharmacy, Medical Licensure Board, and the 
Cabinet for Health and Family Services, the latter of whom would be charged with establishing 
the program (Kentucky Legislative Research Commission, 2003).  
 KASPER benefited early on from high level bipartisan political support and backing from 
a wide range of professionals and community members. This buy-in helped secure a 
comprehensive bill passed with little compromise and adequately designated funding. At the 
time KASPER went into effect, its start-up and projected annual operational costs were among 
the highest for a PDMP at $415,000 and $500,000 respectively. Start-up costs were paid with 
state and federal funds and annual operational costs were earmarked in the state’s annual budget. 
No fees were imposed on the physicians or pharmacists who would access the system. Within 3 
years of implementation, the average length of investigation into alleged “doctor shopping” cases 
plummeted from more than 5 months to just 16 days  (General Accounting Office, 2002). Prior 
to KASPER, Kentucky ranked second in the nation in nonmedical prescription painkiller use. As 
of 2013, Kentucky had fallen to thirty-first place (Substance Abuse and Mental Health Services 
Administration, 2013).  
 Despite its early success, Dave Hopkins, KASPER Program Manager for the Kentucky 
Cabinet for Health and Family Services, considers the program a work in progress. In 2003, the 
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state invested $1.4 million to enhance KASPER (eKASPER), the chief improvement being a 
shift away from a fax-based reporting system to one that was entirely web-based in order to cut 
down on costs and report request turnaround. In 2006, Kentucky pharmacists were required to 
report within 8 days of dispensing a controlled substance rather than the 16 day window 
previously mandated. Keeping in line with the ultimate goal of real time reporting that was set in 
2006 (Kentucky Cabinet for Health and Family Services, 2006), in July of 2013, that window 
was shortened to just one day (Substance Abuse and Mental Health Services Administration, 
2013). This innovative attitude has allowed Kentucky to respond quickly to changes in 
prescription drug abuse trends, to rapidly adopt new technology as it becomes available, to 
maintain stakeholder cooperation and satisfaction, and to work with other states to help improve 
their PDMPs. In 2013, Kentucky’s commitment to having an adaptive and highly advanced 
PDMP earned it the “gold standard” label from SAMHSA (Substance Abuse and Mental Health 
Services Administration, 2013).   
 
Florida 
 One of only 17 states in 2010 without an operational PDMP, Florida had become the 
nation’s largest provider of prescription painkillers. That year Florida practitioners purchased 44 
times as many dosage units of oxycodone as Ohio, the number two state on the list (Office of 
National Drug Control Policy, 2011). As Kentucky and its border states cracked down on “doctor 
shopping,” area users and dealers increasingly turned to pain management treatment facilities in 
Florida to supply large quantities of painkillers. Demand drove supply and by 2010, Florida was 
home to over 900 unregulated pain management clinics and 49 of the top 50 oxycodone 
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dispensing clinics in the nation. Forty-five of those clinics were located in Broward County alone 
(Florida PDMP Foundation Inc., 2014a).  
In 2009, Florida State Attorney Michael Satz issued an official report titled “The 
Proliferation of Pain Clinics in South Florida.” According to Satz, legitimate pain management 
facilities were eclipsed by storefront businesses looking to capitalize on the influx of eager 
shoppers. Florida’s lax prescription drug oversight helped attract that business by allowing the 
legal prescription of enormous quantities of powerful opioids and benzodiazepines to users and 
dealers under the guise of treatment. These pill mills, as they are known, advertise aggressively, 
offering services like onsite prescription dispensing and walk-in availability. Most of these 
facilities would charge a fee of between $99 and a few hundred dollars to undergo the formality 
of diagnosis. Most all accept cash only so as not to tip off public or private insurance providers 
to high volume dispensing. A typical prescription at one of these facilities might include a 
cocktail of 4 different painkillers, muscle relaxants, and anti-anxiety medications, for a total of 
420-540 pills having a street value of $3,000-$5,000 or more. With no prescription drug 
monitoring program in place, patients were free to visit multiple pill mills to fill several such 
prescriptions in a very short period of time without being detected. The business was so lucrative 
that between August, 2008 and November 2009, a new pain clinic opened every 3 days in 
Broward and Palm Beach counties alone (Satz, 2009).        
 
E-FORCSE 
  Several states recognized the burden that Florida pill mills’ loose prescribing practices 
placed on their own efforts to curb prescription drug diversion at home. Kentucky was among the 
most vocal, with urgent calls coming from the Governor, Attorney General, and Lieutenant 
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Governor (a former physician in Hazard, Kentucky) for Florida to enact a prescription drug 
monitoring program. Florida’s Office of the Attorney General cited prescription drug abuse as 
the state’s “fastest-growing and deadliest public safety issue,” caused chiefly by Florida’s “weak 
regulatory oversight” and lack of prescription drug monitoring program (Florida Office of the 
Attorney General, 2015, p.6). State institutions such as the Florida Department of Health and 
Florida Sheriffs Association ardently supported passage of prescription drug database legislation. 
Federal entities, too, recommended Florida establish a PDMP to help curb prescription drug 
abuse locally and across state borders. Despite this widespread multi-disciplinary backing, 
Florida Legislature refused to pass relevant legislation calling for the enactment of a prescription 
drug monitoring program for seven straight years, beginning in 2002. 
Political opposition to a Florida PDMP began at the top in the office of Governor Rick 
Scott. A Tea Party conservative, Scott’s public business stance was one of limited government 
intrusion into free market practice. Prior to pursuing office, Scott gained prominence as a co-
founder of Solantic, a chain of urgent care centers. He served on the board until his bid for the 
governorship at which time he transferred his $62 million dollar interest in the company to his 
wife. Scott claimed no legal conflict of interest since the company shares were no longer 
technically in his name, however, some speculate these household finances play a big role in his 
reluctance to back any program that could have a chilling effect on the medical services industry 
in Florida (Hundley, 2011). 
 In 2009, ten years after Kentucky had taken its first legal step toward implementing 
KASPER, and at a time when an average of 10 Floridians were dying each day due to 
prescription overdose, Florida lawmakers passed legislation calling for the establishment of a 
PDMP  to monitor the dispensation of controlled substances in Schedules II, II, and IV. Then 
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Governor Charlie Crist signed the bill into law. His successor would not be so supportive. Soon 
after initial E-FORCSE legislation passed, two years before becoming operational, newly elected 
Governor Scott added a clause to his annual budget proposal calling for the repeal of the new 
legislation, stating “that program has not been working” (Zink & Martin, n.d., p.1). Though his 
effort failed, Scott did successfully dismantle Florida’s Office of Drug Control, the leading state 
agency, alongside the state Department of Health, charged with planning and implementing the 
PDMP, prior to the program’s launch (Zink & Martin, n.d.). Regardless of whether the motive is 
one of philosophy or finance, significant improvement efforts to Florida’s PDMP may be most 
effective if developed at the prescriber/dispenser level rather than legislative level at least until 




The National Institute on Drug Abuse funded study “Social Networks and HIV Risk 
among Rural Drug Users” (known colloquially as the Social Networks among Appalachian 
People or “SNAP” study) was a longitudinal exploratory study conducted in Hazard, Kentucky 
by the University of Kentucky’s Center on Drug and Alcohol Research. Eligibility criteria 
required participants to be at least 18 years of age at the time of baseline interview, reside within 
an Appalachian county in Kentucky as designated by the Appalachian Regional Convention 
(Figure 1), and report having used heroin, crack/cocaine, methamphetamines, or prescription 
opioids for non-medical purposes in the 30 days prior to screening. The study was populated 
using respondent driven sampling (RDS). In addition to the aforementioned eligibility criteria, 
initial respondents were also required to report a lifetime history of injection drug use. Upon 
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enrollment and completion of the baseline interview, these seed participants were given 3 
coupons (business cards with 3 unique referral codes assigned to each participant) to distribute to 
their drug using peers who were deemed eligible following the above criteria regardless of 
injection history.  RDS is a recruitment strategy regarded for its ability to leverage a network’s 
existing social capital to access hidden populations such as injection drug users (IDUs). 
Employing RDS is particularly advantageous in rural communities where pockets of potential 
participants may be geographically isolated and fall outside the purview of other recruitment 
methods.      
 
Figure 1. Appalachian Regional Commission County Economic Status in Appalachia, FY 2009, adapted to identify the 
Hazard, KY region and location of the SNAP study. 
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Participation consisted of a baseline and three follow-up engagements at 6, 12, and 18 
months post-baseline, each of which involved an interviewer-administered questionnaire 
followed by human immunodeficiency virus (HIV), hepatitis C (HCV), and herpes simplex virus 
2 (HSV-2) rapid screening, and urine drug screening analysis. HIV screening was conducted 
using OraQuick oral swab testing kits which screened for the presence of HIV antibodies. Biokit 
HSV-2 rapid tests involved a finger stick and screened specifically for the HSV-2 virus. Both 
HIV and HSV-2 results were available within 20 minutes of specimen collection. Home Access 
HCV antibody tests required a dried blood specimen, collected from the same finger stick as was 
used for HSV-2 test specimen collection. Samples were shipped to Home Access lab for 
analysis. Participants were asked to return to the study site approximately 2 weeks later to 
receive results and post-test counseling. Participants visiting the office to receive HCV results 
between follow-up appointments were compensated $10 for their time. Otherwise, results were 
given at the next contact. All results were given verbally. A reactive HIV test, would prompt an 
immediate confirmatory Western Blot blood test, none of which were necessary during the 
course of the study. Interviewers were trained to conduct pre- and post-test counseling and were 
state certified HIV counselors. 
Participation was confidential, protected by a federal certificate of confidentiality, and 
individuals were compensated $50 for each visit. Participants were given a $25 bonus for 
completing all four visits. Seed participants (n=107) were compensated $10 for each referral who 
successfully completed baseline, up to a maximum of three referrals. All baseline interviews 
were conducted in a storefront office in downtown Hazard, though circumstances necessitated 
some follow-ups be conducted in participant homes, public libraries, and controlled facilities 
such as rehabilitation centers, regional jails, and prisons both inside and outside of the region, 
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observing the same consideration for confidentiality as in the office setting. Incarceration and/or 
in-patient rehabilitation status, which could affect previous 30 day drug use, at the time of, or 
between, follow-ups was not availed for analysis. 
Personal Affiliation Disclosure Statement: The writer discloses his role as Data 
Coordinator and Administrative Research Assistant Principal on the study from 
September, 2008 through November, 2012, however, he does not believe this to present a 
conflict of interest or serve as a detriment to the integrity of this paper’s analysis in any 
way. 
 
Recruitment began September, 2008 and ended August, 2010 with 506 participants 
enrolled. Three individuals reported discrepant drug use between screening and baseline and 
were removed from the study as a result for a final sample size of 503 participants. (Figure 2) 
Figure 2. 
 
The study was eventually extended to include two additional follow-ups at 24 and 30 months 
post-baseline. Retention rates achieved at each time point follow: 94.4% (n=475) at 6 months; 
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93.2% (n=469) at 12 months; 95.0% (n=478) at 18 months; 86.5% (n=435) at 24 months; and 
82.5% (n=415) at 30 months. (Figure 2) 
 
Secondary Data Analysis 
For the purpose of this paper, 2,775 surveys, administered between November 14, 2008 
and August 6, 2014, were assessed. Four surveys (two 6-month, one 12-month, and one 18-
month follow-up) were missing their corresponding date and were discarded for a total of 2,771 
surveys reviewed. Survey data was cleaned of all personal identifiable participant information 
before access was granted for secondary analysis, for which IBM SPSS Statistics version 22 was 
used. For temporal comparison, raw study data was divided into 13 6-month epochs.  
 
Hazard, Kentucky 
 Hazard is the county seat of Perry County, a coal producing county situated in the central 
Appalachian mountains of eastern Kentucky. With an estimated population of 5,432 residents in 
2013 (U.S. Census State & county Quickfacts: Hazard, KY), it is also the county’s largest town. 
Perry County, population 27,899, has a poverty rate of 25.8%, (1.73 times the national average) 
and borders 7 other Kentucky counties, all of which are designated economically distressed 
(worst 10% of the nation’s counties) by the Appalachian Regional Commission (Appalachian 
Regional Commission, 2008). Hazard is located 60 miles from the nearest interstate, which may 
account, in part, for its opiate using residents’ predilection toward prescription opioids rather 
than heroin as the latter does not tend to be in consistent supply so far removed from urbanized 
areas. Hazard lies within 150 miles of 5 other states (Ohio, West Virginia, Virginia, North 
Carolina, and Tennessee), affording a reasonable opportunity to interstate “doctor shoppers”.  
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Hazard gained national recognition when it was featured as part of Newsweek’s April 9, 
2001 cover story on illicit prescription opioid abuse. In 2000, per capita distribution of 
OxyContin, oxycodone excluding OxyContin, and hydrocodone in Perry County was 
respectively 5.6 times, 3.5 times, and 5.4 times the national average. Among Kentucky counties, 
Perry County ranked second  in OxyContin and hydrocodone distribution and first in non-
OxyContin oxycodone distribution (Van Zee, 2009). The Newsweek article focused heavily on 
the behaviors of a few rather than the political and socioeconomic drivers of addiction in the 
region. Still, the article played an important role in drawing national media attention to the 
growing trend of oxycodone abuse (Kalb, 2001).  
 
RESULTS 
Over the course of the SNAP study, two major prescription drug abuse prevention 
strategies were employed that may have contributed to a shift in drug use patterns and 
preferences among participants. (Figure 3) Purdue Pharma replaced its original OxyContin with 
a tamper-resistant product, and Kentucky introduced House Bill 1. 
  





1. Tamper-resistant OxyContin 
Responding to a growing body of scientific evidence of their role in the nation’s 
prescription drug epidemic and mounting public pressure to reduce the ease with which their 
most popular drug was commonly abused, Purdue Pharma developed a tamper-resistant 
OxyContin approved by the FDA in April, 2010 to replace the existing formula. The 
reformulated pill prevented users from circumventing the time release feature by turning the pill 
into a gel when crushed, broken, or introduced to water, thereby preventing injection or 
insufflation. It did not deter misuse by means of oral ingestion. The new formulation appeared on 
pharmacy shelves in August of 2010 (National Association of Boards of Pharmacy, 2010). By 
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retail stores in the United States. No participant cited doctor or dentist as their prior 6 month 
primary source after November of 2010, however reports of occasional dealer availability 
persisted into 2013 at a street price of $1.50 - $2.00 per milligram (and in some isolated cases as 
much as $2.50 per milligram or $200 per 80mg pill) compared to the usual $1 per mg street price 
reported prior to formula’s discontinuation.  Upon expiration of Purdue Pharma’s original 
OxyContin formula patent in November, 2012, Health Canada approved the manufacturing of 
generic non-tamper resistant oxycodone formulations (Healthy Canada, 2012). No participants 
reported knowingly using the Canadian formulation. 
The proportion of SNAP participants reporting past 30 day new or old formula 
OxyContin use fell sharply from 72% in the first half of 2009 to just 29% two years later while 
other oxycodones like Roxicodone filled the immediate gap (Figure 3; Figure 4). Buprenorphine, 
an opioid replacement therapy drug, steadily gained favor among the cohort. Suboxone 
sublingual strips containing naloxone were the most commonly reported form of the drug used. 
Buprenorphine is an opioid antagonist however; its high is notably mellower than traditional 
opioids including methadone, another replacement therapy drug. In 2009, participants were more 
than 25 times (81:3) as likely to have used buprenorphine without a prescription as well; 
however, reports of legally prescribed buprenorphine use grew, accounting for 17.7% of all 
reports of prior 30 day use after 2009.  The naloxone ingredient’s anti-opioid quality discourages 
simultaneous opioid use by inducing rapid withdrawal, therefore, the argument can be made that 
Suboxone adoption, whether legal or illegal, signals positive behavior change in this cohort of 
opioid users. Furthermore, the overwhelming tendency for users to obtain Suboxone via illicit 
means indicates obstacles to legitimate replacement therapy enrollment for those seeking 
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sobriety. The impact on the cost and availability of this product should be addressed in order to 
maximize Suboxone’s rehabilitative potential among rural drug users.  
Figure 4.  
 
Of the 200 participants who identified the original OxyContin formulation as their drug 
of choice, 35.5% said they preferred Roxicodone (an instant release oxycodone hydrochloride 
commonly available in 30mg non-tamper resistant tablets); 26.5% reported a preference for 
buprenorphine, and 11.5% reported that they were no longer using at 30 months post-baseline. 
(Figure 4) Contrary to popular concern, only 3 of the 200 participants (1.5%) reported a primary 
preference for heroin, and only 2 reports of heroin use in all 30 of the previous 30 days were 
made over the course of the entire study. Furthermore, only 3.3% of participants at 30 month 
follow-up stated they “would use heroin if it were readily available,” indicating lack of 
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from illicit prescription opioid to heroin use. In 2013 the majority of heroin implicated overdose 
deaths in the Kentucky were still clustered around the state’s three major urban areas, Louisville, 
Lexington, and the suburbs of Cincinnati (Kentucky Office of Drug Control Policy, 2013). 
The discontinuation of Purdue Pharma’s original OxyContin formula had a profound 
effect on opioid misuse trajectories in this Kentucky population; however continued use of other 
prescription oxycodones underscores the need for additional prevention methods. Eliminating a 
single source or formula with significant abuse potential is a step in a long process rather than 
the solution itself. Pharmaceutical companies requesting the FDA’s approval for future opioids 
should be prepared to face additional scrutiny in line with the level that might have prevented the 
prescription drug addiction epidemic fueled by the original OxyContin formula.  
2. Kentucky House Bill 1 
In 2012 the Kentucky General Assembly passed House Bill 1 (HB1) to address 
deficiencies in the regulation of the administration, prescription, and dispensation of controlled 
substances (Kentucky Board of Medical Licensure, 2012). The bill’s primary aims were to 
reduce number of controlled substances (schedules II & III containing hydrocodone) on the street 
by prohibiting the licensure of prescribers who were not registered with KASPER, and to 
empower prescribers, dispensers, and patients to recognize certain natural “decision points” in 
the pain management process.  These were points at which parties could evaluate an approach’s 
efficacy and decide whether treatment should be modified or continue unchanged. HB1’s two 
major components included mandatory KASPER registration by any prescriber or pharmacist 
with controlled substance prescription or dispensation authorization and reporting of said 
prescription or dispensation to KASPER within one day. More frequent and extensive review of 
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patients’ KASPER reports prior to initial prescription of a schedule II controlled substance or 
schedule III controlled substance containing hydrocodone was also ordered.  
The bill passed in April, 2012, and in his 2013 State of the Commonwealth speech, 
Governor Steve Beshear praised the bill as “landmark prescription painkiller legislation” that 
distanced Kentucky from the “prescription playground” it was prior to the bill’s passage. Beshear 
credited the bill with contributing to a seven-fold increase in KASPER use as well as the closure 
of nearly half of Kentucky’s known pain management clinics (Beshear, 2013). Reported illicit 
methadone use among SNAP study participants fell 70% between the second half of 2012 and 




 Florida PDMP enactment legislation is unique in that it explicitly prohibits use of state 
revenue unless authorized by vote as well as disallows donations either directly or indirectly 
made by pharmaceutical companies (Florida PDMP Foundation Inc., 2014b). Instead, E-
FORCSE relies on federal grants and to a greater extent, private grants and donations. As of 
2013, Florida was the only state to solicit private donors. The Florida PDMP Foundation, whose 
11 member board is appointed by the state Surgeon General, was established to secure and 
manage these funds. Relying on donors for primary funding is problematic for a multitude of 
reasons – long-term planning is compromised due to resource instability; development players 
are locked in an exhaustive and continual cycle of raising funds.  
Before measures can be taken to expand the scope and reach of Florida’s E-FORCSE, a 
concerted effort must be made to secure adequate and consistent funding to sustain existing 
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infrastructure as well as any proposed expansion long term. Florida is the only state that relies on 
private donations to operate its PDMP, a position that leaves it susceptible to abrupt 
discontinuation should fundraising efforts fall short any given year. Amending legislation to 
permit the use of $600,000 of state revenues annually to fund E-FORCSE is the ideal solution 
(Brandeis University Prescription Drug Monitoring Program Training and Technical Assistance 
Center, 2013). Unfortunately, the program is a politically divisive one among Florida’s state 
lawmakers, many of whom campaigned against initial legislation until language explicitly 
revoking the state’s proposed fiscal involvement was added.  
An intersectoral cost effectiveness analysis of potential savings to the state by investing 
in its PDMP should be carried out to ensure complete buy-in from policymakers regardless of 
their motivation or affiliation. Nationally, estimated costs associated with prescription opioid 
abuse in 2007 totaled $55.7 billion. Workplace, health care, and criminal justice costs accounted 
for 46%, 45%, and 9% of the total respectively (Birnbaum et al., 2011). Proponents should 
analyze and publicize Florida-specific costs in much the same manner when addressing elected 
officials and their constituents in order to appeal to the fiscal benefits of the state to promote 
investing in the program.  
 
Electronic Database Interface 
 A PDMP satisfaction survey among users and non-users of E-FORCSE conducted Spring 
2013 by the Florida Department of Health revealed that technical issues were among physicians’ 
and prescribers’ chief complaints. Respondents cited password issues, prohibitively specific 
patient search criteria, system lag time, and overall webpage design as primary technical 
compliance obstacles (Florida Department of Health, 2013). Respondents also noted that these 
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issues increased the amount of time spent on each patient, effectively serving as an economic 
deterrent to compliance. A well-funded system that is not easily accessible cannot be expected to 
operate to its fullest potential as a prevention tool. Efforts should be made to develop an intuitive 
electronic database interface in order to streamline access and reduce user burden.  
In January 2015 the electronic system was updated to allow for more intuitive navigation 
and uniformity between forms. Additionally, issues explicitly stated in the satisfaction survey 
were addressed, including the ability to more easily retrieve forgotten usernames and passwords 
and a search query more responsive to misspelled names. Registered users were notified in 
advance of the system update and video tutorials were published to acclimate practitioners to the 
redesigned site. While it is too soon to evaluate the functionality of the update, the fact that the 
most frequently addressed concerns from the 2013 survey were addressed in the update is 
promising. Managers of the online database should use the overhaul’s announcement webpage 
(where tutorials are housed) as a repository for other educational materials about underutilized 
features. A brief follow-up survey should be issued to registered users 3-6 months post-launch 
and conducting comprehensive satisfaction surveys such as 2013’s should be continued 
periodically to drive evidence based decision-making regarding future system updates (Health 
Information Designs, 2015).    
 
Interstate Operability 
 PDMPs are implemented at the state level, so unless provisions are made with other 
states to communicate recorded prescription and dispensation data across borders, “doctor 
shoppers” only need travel to a nearby state with looser prescription oversight to secure 
additional pills. Recognizing this major loophole, Kentucky coordinated with three other central 
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Appalachian states – Tennessee, Ohio, and West Virginia – in 2011 to form a task force focused 
on recommending best practices and developing strategies with other states to insure the integrity 
of their own PDMPs and so state systems were not undermined by interstate prescription drug 
trafficking. That same year Kentucky and Ohio launched the electronic Prescription Monitoring 
Information Exchange (PMIX), the first automated interstate exchange (IJIS Institute, 2011). The 
goal of the program was to develop an interstate repository of individual state PDMP data, whose 
population and report access would be both secure and streamlined, reducing user burden.  
Once again, Kentucky found itself at the leading edge of PDMP innovation. However, the 
state was still inundated by easy access to prescription drugs in other states like Florida. In 2000, 
Kentucky Governor Steve Beshear estimated that 60% of his state’s illicit prescription drugs 
originated in Florida. December 9, 2011 Florida’s Department of Health recommended interstate 
operability. The sentiment is echoed by the Department of Health and Human Services as well as 
leaders in other states (Congressional Research Service, 2014). Florida pharmacists and 
prescribers cited the inability to communicate across state lines a substantial problem, 
particularly considering the state’s enormous domestic tourism industry (Florida Department of 
Health, 2013). The number of states establishing interstate operability has grown significantly in 
the years since, from 14 states in 2012 to 28 in 2014; still Florida is not among them (Brandeis 
University Prescription Drug Monitoring Program Training and Technical Assistance Center, 
2014).     
Federal grants such as those allocated by the Harold Rogers Prescription Monitoring 
Program should be secured to develop a thorough and secure interstate compact between Florida 
and other states engaging in PMIX. Such an agreement would not only benefit states burdened 
by Florida’s prescription drug overflow, but also streamline data entry and report generation by 
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and for prescribers, dispensers, and investigators at the local level. Metrics of success would 
include number of reports requested internally and from other states, number of records 
submitted, length of criminal investigations into suspected prescription drug diversion involving 
Florida clinics, and general satisfaction reported by physicians and dispensers on future 
comprehensive user satisfaction surveys.  
 
CONCLUSION 
Despite having one of the strongest PDMPs in the nation, Kentucky continues to struggle 
against an influx of prescription opioids diverted for misuse from other states, over half of which 
are estimated to come from Florida alone. Extensive programmatic expansion and other such 
sweeping changes to E-FORCSE at the legislative level are unlikely given present political 
leadership in Florida. Focusing efforts on updating individual, more viable elements of the E-
FORCSE system may prove more beneficial in the near term while building the evidence-based 
case for future expansion in the long-term. Consistent funding, a streamlined user interface, and 
interstate operability are vital to the success of any future expansion. By implementing best 
practices demonstrated by other states’ successful PDMP initiatives (e.g., KASPER), Florida 
could significantly contribute to reducing the blight of prescription opioid abuse throughout 
eastern Kentucky, central Appalachia, and at home.    
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